Leyden Labs Secures $70 Million Funding to Develop Broad Protection Against Respiratory Viruses

Funding:
Leyden Labs, a Dutch startup, has raised $70 million in funding to develop broad protection against respiratory viruses such as influenza and coronaviruses1.

Investors:
The funding was co-led by ClavystBio and Polaris Partners, with participation from Qiming Venture Partners and existing investors including GV, Casdin Capital, F-Prime Capital, and Softbank Vision Fund 21.

Use of Funds:
The funds will be used to support further development of Leyden Labs' pipeline, including human efficacy studies of PanFlu, advancements in its Mucosal Protection Platform research, and other pipeline activities1.

Acquisition:
Leyden Labs also announced the acquisition of CoV Biotechnology Pte. Ltd., a Singaporean biotech company, to enhance its research and development efforts in pandemic preparedness and partnership initiatives in Asia1.

Platform:
Leyden Labs' platform targets commonalities of viral families to provide broad protection against many viruses simultaneously, unlike traditional vaccines that protect against specific virus variants1.

Nasal Sprays:
The company is advancing a novel class of broadly protective nasal sprays, including its PanFlu candidate containing the monoclonal antibody CR9114, for influenza prophylaxis1.

Mission:
Leyden Labs aims to stop infections early by delivering antibody-based formulations directly to the nasal mucosa, eliminating the threat of respiratory viruses at the point of entry1.

Sources:

1. https://techfundingnews.com/leyden-labs-raises-70m-to-protect-against-influenza-and-other-respiratory-viruses/